Search Results

You are looking at 41 - 50 of 1,651 items for :

  • "chemotherapy" x
Clear All
Full access

Laura Spring, Rachel Greenup, Andrzej Niemierko, Lidia Schapira, Stephanie Haddad, Rachel Jimenez, Suzanne Coopey, Alphonse Taghian, Kevin S. Hughes, Steven J. Isakoff, Leif W. Ellisen, Barbara L. Smith, Michelle Specht, Beverly Moy and Aditya Bardia

young women with breast cancer. Neoadjuvant chemotherapy (NAC) is being increasingly used in the management of localized breast cancer as an alternative to adjuvant chemotherapy. Studies have shown that the benefit of chemotherapy is similar when given

Full access

Christopher M. Booth, Sulaiman Nanji, Xuejiao Wei, Yingwei Peng, James J. Biagi, Timothy P. Hanna, Monika K. Krzyzanowska and William J. Mackillop

Background International treatment guidelines have recommended 5-fluorouracil (FU)–based adjuvant chemotherapy (ACT) for patients with stage III colon cancer since the 1990s. 1 This is based on a series of randomized controlled trials (RCTs

Full access

Zi-Xian Wang, Hao-Xiang Wu, Ming-Ming He, Ying-Nan Wang, Hui-Yan Luo, Pei-Rong Ding, Dan Xie, Gong Chen, Yu-Hong Li, Feng Wang and Rui-Hua Xu

efficacy of chemotherapy + cetuximab (Cet) or panitumumab (Pani) versus chemotherapy ± bevacizumab (Bev) reported significant improvement in overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) with chemotherapy + Cet

Full access

Michaela A. Dinan, Lauren E. Wilson and Shelby D. Reed

Background The introduction of genomic tests such as the Oncotype DX 21-gene recurrence score (RS) assay has allowed the omission of adjuvant chemotherapy for patients with estrogen receptor (ER)–positive, node-negative breast cancer who have a low

Full access

Prashant Gabani, Emily Merfeld, Amar J. Srivastava, Ashley A. Weiner, Laura L. Ochoa, Dan Mullen, Maria A. Thomas, Julie A. Margenthaler, Amy E. Cyr, Lindsay L. Peterson, Michael J. Naughton, Cynthia Ma and Imran Zoberi

advanced TNBC typically receive chemotherapy, surgery, and radiation therapy (RT). More recently, the concept of neoadjuvant chemotherapy (NAC) followed by surgery and RT has been introduced in women with locally advanced or palpable TNBC, 6 because TNBC

Full access

Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II and Chi Lin

GC include chemotherapy (CT) alone or chemoradiotherapy (CRT), although it is noted that there are limited data to support the CRT option. 1 Although the addition of local therapy for unresected GC is controversial, it is theoretically appealing for

Full access

Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico and Mark F. Berry

Background Adjuvant chemotherapy (AC) after resection of stages II through IIIA non–small cell lung cancer (NSCLC) has repeatedly been shown to improve survival. 1 – 6 NCCN and ASCO therefore both recommend AC for patients with completely

Full access

Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert and Leah L. Dietrich

No definite preferred standard of care exists for adjuvant chemotherapy (ACT) in patients with node-negative, HER2-positive breast cancers measuring <2 cm. 1 Prior to the advent of HER2-directed therapy, HER2 overexpression was a marker of poor

Full access

Heike Reinhardt, Rainer Trittler, Alison G. Eggleton, Stefan Wöhrl, Thomas Epting, Marion Buck, Sabine Kaiser, Daniel Jonas, Justus Duyster, Manfred Jung, Martin J. Hug and Monika Engelhardt

professionals, with an increased demand for sterile production of chemotherapy drugs within existing workforce constraints. Resulting financial implications are also considerable. For the National Health Service (NHS) in England, for example, chemotherapy is the

Full access

Marina Stasenko, R. Kevin Reynolds, Carolyn Johnston, Melissa Brackman, Karen McLean and Shitanshu Uppal

peritoneal cancers undergo treatment consisting of both surgical debulking and chemotherapy. Conventional chemotherapy includes intravenous carboplatin and paclitaxel administered every 3 weeks for 6 cycles. 2 The Gynecologic Oncology Group (GOG)-172